Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market

CRISPR Therapeutics AG (CRSP) declined 5.34% on October 30, 2026, underperforming the S&P 500's 1.82% loss. Despite strong projected revenue growth of 1017.42% for the upcoming quarter and 824.53% for the full year, the stock fell short of market expectations. The company holds a Zacks Rank #3 (Hold) rating with consensus EPS estimates slightly improving by 0.59% over the last 30 days.